comparemela.com

Latest Breaking News On - Venture partners investment advisor - Page 2 : comparemela.com

IO Biotech's (IOBT) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IO Biotech (NASDAQ:IOBT – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $8.00 price objective on the stock. IO Biotech Price Performance Shares of NASDAQ IOBT opened at $1.82 on Wednesday. IO Biotech has a 1 year […]

Io-biotech-inc
Vivo-capital
Stonepine-capital-management
Armistice-capital
Venture-partners-investment-advisor
Holdingsas-novo
Citadel-advisors
Free-report
Capital-management
Get-free-report

Holdings A/S Novo Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT) Stock

Holdings A/S Novo Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Venture-partners-investment-advisor
Io-biotech-company-profile
Citadel-advisors
Holdingsas-novo
Io-biotech-inc
Morgan-stanley
Vivo-capital
Nasdaq
Get-free-report
Street-group

Gracell Biotechnologies Inc. (NASDAQ:GRCL) Given Consensus Recommendation of "Moderate Buy" by Analysts

Gracell Biotechnologies Inc. (NASDAQ:GRCL) Given Consensus Recommendation of "Moderate Buy" by Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Nasdaq
Wells-fargo-company
Vivo-capital
Cantor-fitzgerald
Gracell-biotechnologies-inc
Oasis-management-co-ltd
Bellevue-group
Venture-partners-investment-advisor
Gracell-biotechnologies
Get-free-report
Marketbeat-ratings

Inozyme Pharma (NASDAQ:INZY) Given Outperform Rating at Wedbush

Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price suggests a potential upside of 172.73% from the stock’s current price. Separately, Needham & Company […]

United-states
Inozyme-pharma
Inozyme-pharma-inc
Eventide-asset-management
Venture-partners-investment-advisor
Needham-company
Get-free-report
Capital-partners
Springs-capital-management
Asset-management
Inozyme-pharma-daily
Nasdaq-inzy

Gracell Biotechnologies (NASDAQ:GRCL) Reaches New 1-Year High at $10.22

Gracell Biotechnologies Inc. (NASDAQ:GRCL – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $10.22 and last traded at $10.21, with a volume of 474243 shares traded. The stock had previously closed at $10.18. Wall Street Analysts Forecast Growth Several research firms […]

Piper-sandler
Capital-group-international-inc
Wells-fargo-company
Nasdaq
Gracell-biotechnologies-company-profile
Gracell-biotechnologies-inc
Venture-partners-investment-advisor
Vivo-capital
Sphera-funds-management
Gracell-biotechnologies
Get-free-report
Funds-management

vimarsana © 2020. All Rights Reserved.